Zobrazeno 1 - 10
of 370
pro vyhledávání: '"Ochi A"'
Autor:
Aya Kuchiba, Katsunori Tsuji, Yutaka Matsuoka, Ryo Okubo, Yoichi Shimizu, Eisuke Ochi, Taichi Shimazu, Naomi Sakurai, Hiroji Iwata, Noriatsu Tatematsu
Publikováno v:
Supportive Care in Cancer. 30:3105-3118
Purpose A known barrier to getting breast cancer survivors (BCSs) to engage in habitual exercise is a lack of information on recommended physical activity levels provided to them by oncology care providers (OCPs). However, the actual situation in Jap
Autor:
Shoichi Kuyama, Kenichiro Kudo, Toshio Kubo, Nobukazu Fujimoto, Akihiro Bessho, Yoshinobu Maeda, Naoyuki Nogami, Makoto Sakugawa, Katsuyuki Hotta, Kadoaki Ohashi, Takashi Ninomiya, Katsuyuki Kiura, Daijiro Harada, Keisuke Aoe, Eiki Ichihara, Daisuke Minami, Keisuke Sugimoto, Nobuaki Ochi, Toshiyuki Kozuki, Nagio Takigawa
Publikováno v:
Japanese Journal of Clinical Oncology. 51:1269-1276
Background In a phase I study, afatinib (30 mg/body daily) plus bevacizumab (15 mg/kg every 3 weeks) was well tolerated and showed favourable outcomes in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer
Autor:
Naofumi Hara, Takuo Shibayama, Yoshinobu Maeda, Katsuyuki Kiura, Shingo Harita, Daizo Kishino, Daijiro Harada, Eiki Ichihara, Nobuaki Ochi, Katsuyuki Hotta, Koji Inoue, Shinobu Hosokawa, Nagio Takigawa, Naohiro Oda
Publikováno v:
European Journal of Cancer. 149:73-81
Background Immune checkpoint inhibitors (ICIs) are essential for treatment of various malignancies, including non–small-cell lung cancer (NSCLC). Recently, several studies have shown that the gut microbiome plays an important role in ICI treatment
Autor:
Hiroaki Mori, Masahiro Nomoto, Jun-ichi Iga, Mariko Ueno, Hiroshi Kumon, Masahiro Nagai, Yu Funahashi, Shu-ichi Ueno, Kiyohiro Yamazaki, Takaaki Mori, Yuki Ozaki, Shinichiro Ochi, Yuta Yoshino
Publikováno v:
Journal of Alzheimer's Disease
Background: Phosphatidylinositol-binding clathrin assembly protein (PICALM) is a validated genetic risk factor for late-onset Alzheimer’s disease (AD) and is associated with other neurodegenerative diseases. However, PICALM expression in the blood
Autor:
Junko Watanabe, Issei Sumiyoshi, Naoko Shimada, Shin-ichiro Iwakami, Kotaro Kadoya, Yusuke Ochi, Kazuhisa Takahashi, Rina Shibayama, Shinsaku Togo, Haruhi Takagi, Hiroaki Motomura, Takahiro Okabe, Moe Iwai, Yuichi Fujimoto, Mizuki Haraguchi
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-11 (2021)
Journal of Translational Medicine
Journal of Translational Medicine
Background Regimens combining pemetrexed (PEM) and immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) or programmed death-ligand 1 (PD-L1) are widely used for the treatment of advanced non-squamous non-small-cell lung cancer
Autor:
T. Ishikawa, M. Imai, Noritomo Shimada, Kazuya Kariyama, Shinya Fukunishi, Akemi Tsutsui, Masashi Hirooka, Hideki Iwamoto, Norio Itokawa, Atsushi Hiraoka, Tomomi Okubo, Ei Itobayashi, Kazuhito Kawata, Joji Tani, Yoichi Hiasa, Kouji Joko, N. Sakamoto, F. Marra, Taeang Arai, Koichi Takaguchi, Francesco Giuseppe Foschi, Masanori Atsukawa, Yohei Koizumi, Marianna Silletta, Massimo Iavarone, Takuya Nagano, J. Siebler, Stefano Cascinu, T. Sho, Margherita Rimini, S. Shigeo, T. Aoki, L. Aldrighetti, Toshifumi Tada, G. Suda, A. Jefremow, V. Burgio, Takashi Niizeki, Hidenori Toyoda, Gianluca Masi, Sara Lonardi, Kazuto Tajiri, F. Ratti, Shinichiro Nakamura, W. Kang, A. Cucchetti, Takashi Kumada, Raffaella Tortora, E. Tamburini, Kunihiko Tsuji, Satoshi Yasuda, Fabio Piscaglia, Hiroshi Shibata, Kazuhiro Nouso, Giuseppe Cabibbo, K. Ueshima, Hironori Ochi, Andrea Casadei-Gardini, Hideko Ohama, T. Takaaki, M. Kudo, M.J. Goh
Publikováno v:
ESMO Open
Background Hepatocellular carcinoma (HCC) treatment remains a big challenge in the field of oncology. The liver disease (viral or not viral) underlying HCC turned out to be crucial in determining the biologic behavior of the tumor, including its resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a91d9d843e6aed5241b4896d5a3f98b8
http://hdl.handle.net/11568/1113875
http://hdl.handle.net/11568/1113875
Autor:
Andrea Casadei‐Gardini, Mario Scartozzi, Toshifumi Tada, Changhoon Yoo, Shigeo Shimose, Gianluca Masi, Sara Lonardi, Luca Giovanni Frassineti, Silvestris Nicola, Fabio Piscaglia, Takashi Kumada, Hyung‐Don Kim, Hironori Koga, Caterina Vivaldi, Caterina Soldà, Atsushi Hiraoka, Yeonghak Bang, Masanori Atsukawa, Takuji Torimura, Kunihiko Tsuj, Ei Itobayashi, Hidenori Toyoda, Shinya Fukunishi, Lorenza Rimassa, Margherita Rimini, Stefano Cascinu, Alessandro Cucchetti, Shinichiro Nakamura, Kojiro Michitaka, Norio Itokawa, Korenobu Hayama, Masashi Hirooka, Yohei Koizumi, Yoichi Hiasa, Toru Ishikawa, Michitaka Imai, Koichi Takaguchi, Akemi Tsutsui, Takuya Nagano, Kazuya Kariyama, Kazuhiro Nouso, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kouji Joko, Satoshi Yasuda, Hideko Ohama, Kazuhito Kawata
Purpose Data from common clinical practice were used to generate balanced cohorts of patients receiving either sorafenib or lenvatinib, for unresectable hepatocellular carcinoma, with the final aim to investigate their declared equivalence. Methods C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb1525de64e54068b735c079325a057e
http://hdl.handle.net/11568/1111033
http://hdl.handle.net/11568/1111033
Autor:
Noritomo Shimada, Akemi Tsutsui, Joji Tani, Kunihiko Tsuji, Koichi Takaguchi, Masanori Atsukawa, Kazuto Tajiri, Hidenori Toyoda, Kojiro Michitaka, Shinichiro Nakamura, Kazuhiro Nouso, Yoichi Hiasa, Kazuya Kariyama, Chikara Ogawa, Yohei Koizumi, Taeang Arai, Toshifumi Tada, Korenobu Hayama, Norio Itokawa, Takashi Kumada, Takuya Nagano, Michitaka Imai, Masatoshi Kudo, Masashi Hirooka, Atsushi Hiraoka, Ei Itobayashi, Hiroshi Shibata, Kazuhito Kawata, Shinya Fukunishi, Toru Ishikawa, Hideko Ohama, Hironori Ochi
Publikováno v:
Gastroenterology Report
Background Lenvatinib is used for unresectable hepatocellular carcinoma (u-HCC) as first-line, as well as second- and third-line therapy in Japan. We evaluated the therapeutic efficacy of newly developed ramucirumab when given after lenvatinib for po
Autor:
Juan A. Kochen Rossi, Ankita Mishra, Berk Aykut, Mautin Hundeyin, Deirdre Jill Cohen, Ece Bagdatlioglu, Atsuo Ochi, Wenyu Su, Joshua Leinwand, Pamela Nassau, Narendra Verma, Mohammed Khan, Jacqueline I. Kim, Nan Wu, Michael Reilly, James H. Thorpe, Aarif Ahsan, Fei Li, Varshini Vasudevaraja, George Miller, Allison M. Beal, Ting Chen, Wei Wang, John D. Lich, Pardeep S. Taunk, Mukesh K. Mahajan, Inedouye Yaboh, Dennis Adeegbe, Jingjing Wu, Philip A. Harris, John Bertin, Johana Gutierrez, Kwok-Kin Wong, Brian Diskin, Emma Kurz, Yue Wu, Christina Almonte, J. Mosley, Michael Glacken, Jill M. Marinis, Shivraj Savadkar
Publikováno v:
Cancer Cell. 38:585-590
Summary Pancreatic ductal adenocarcinoma (PDA) is characterized by immune tolerance and immunotherapeutic resistance. We discovered upregulation of receptor-interacting serine/threonine protein kinase 1 (RIP1) in tumor-associated macrophages (TAMs) i
Autor:
Daisuke Minami, Hiromi Watanabe, Katsuyuki Hotta, Masahiro Tabata, Kenichiro Kudo, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Etsuko Murakami, Kammei Rai, Nobuaki Ochi, Kiichiro Ninomiya, Katsuyuki Kiura, Kadoaki Ohashi, Daijiro Harada, Yoshinobu Maeda, Masayuki Yasugi, Keiichi Fujiwara
Publikováno v:
Japanese Journal of Clinical Oncology. 50:1447-1453
Objectives Immune checkpoint inhibitors offer longer survival than chemotherapy in several clinical trials for advanced non-small cell lung cancer. In subset analyses of clinical trials, immune checkpoint inhibitors extended survival in patients aged